Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Chiesi Drug Patent Portfolio

Chiesi owns 12 orange book drugs protected by 63 US patents with Zyflo Cr having the least patent protection, holding only 1 patent. And Mycapssa with maximum patent protection, holding 14 patents. Given below is the list of Chiesi's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11141457 Oral octreotide therapy and contraceptive methods 28 Dec, 2040
Active
US11890316 Oral octreotide therapy and contraceptive methods 28 Dec, 2040
Active
US11083733 Betulin-containing birch bark extracts and their formulation 04 Jan, 2039
Active
US11266660 Betulin-containing birch bark extracts and their formulation 04 Jan, 2039
Active
US10780055 Delayed release deferiprone tablets and methods of using the same 25 Oct, 2038
Active
US10940115 Delayed release deferiprone tablets and methods of using the same 25 Oct, 2038
Active
US10940116 Delayed release deferiprone tablets and methods of using the same 25 Oct, 2038
Active
US11357731 Delayed release deferiprone tablets and methods of using the same 25 Oct, 2038
Active
US11458103 Delayed release deferiprone tablets and methods of using the same 25 Oct, 2038
Active
US11723874 Delayed release deferiprone tablets and methods of using the same 25 Oct, 2038
Active
US10238709 Method of treating diseases 03 Feb, 2036
Active
US10695397 Method of treating diseases 03 Feb, 2036
Active
US11052126 Method of treating diseases 03 Feb, 2036
Active
US11338011 Method of treating diseases 03 Feb, 2036
Active
US11510963 Method of treating diseases 03 Feb, 2036
Active
US11857595 Method of treating diseases 03 Feb, 2036
Active
US10039780 Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same 10 Jul, 2035
Active
US9295687 Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same 10 Jul, 2035
Active
US9439921 Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same 10 Jul, 2035
Active
US9700575 Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same 10 Jul, 2035
Active
US8680052 Methods of treating, reducing the incidence of, and/or preventing ischemic events 09 Mar, 2033
Active
US10010537 Clevidipine emulsion formulations containing antimicrobial agents 10 Oct, 2031
Active
US11103490 Clevidipine emulsion formulations containing antimicrobial agents 10 Oct, 2031
Active
US8658676 Clevidipine emulsion formulations containing antimicrobial agents 10 Oct, 2031
Active
US9352041 Use of an oleogel containing triterpene for healing wounds 24 Nov, 2030
Active
US9827214 Use of an oleogel containing triterpene for healing wounds 24 Nov, 2030
Active
US9427448 Methods of treating, reducing the incidence of, and/or preventing ischemic events 10 Nov, 2030
Active
US8703156 Liquid formulation for deferiprone with palatable taste 26 Oct, 2029
Active
US11969471 Pharmaceutical compositions and related methods of delivery 17 Sep, 2029
Active
US11986529 Pharmaceutical compositions and related methods of delivery 17 Sep, 2029
Active
US8329198 Pharmaceutical compositions and related methods of delivery 17 Sep, 2029
Active
US8535695 Pharmaceutical compositions and related methods of delivery 17 Sep, 2029
Active
US9265812 Pharmaceutical compositions and related methods of delivery 17 Sep, 2029
Active
US9566246 Pharmaceutical compositions and related methods of delivery 17 Sep, 2029
Active
US8759316 Maintenance of platelet inhibition during antiplatelet therapy 13 May, 2029
Active
US9925265 Methods of treating or preventing stent thrombosis 13 May, 2029
Active
US7612102 Pre-mixed, ready-to-use pharmaceutical compositions 26 Dec, 2027
Active
US9364564 Pre-mixed, ready-to-use pharmaceutical compositions 26 Dec, 2027
Active
US7932268 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects 19 Aug, 2027
Active
US10758616 Pre-mixed, ready-to-use pharmaceutical compositions 18 Apr, 2027
Active
US11547758 Pre-mixed, ready-to-use pharmaceutical compositions 18 Apr, 2027
Active
US7659291 Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions 18 Apr, 2027
Active
US8455524 Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions 18 Apr, 2027
Active
US8828444 Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel 21 Jun, 2025
Active
US10016404 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects 07 Mar, 2025
Active
US10555938 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects 07 Mar, 2025
Active
US8618135 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects 07 Mar, 2025
Active
US9265758 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects 07 Mar, 2025
Active
US9364470 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects 07 Mar, 2025
Active
US9433617 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects 07 Mar, 2025
Active
US9861622 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects 07 Mar, 2025
Active
US6130208 Formulation containing a nucleotide analogue 29 Jun, 2023 Expired
US7696178 Optimised formulation of tobramycin for aerosolization 17 Mar, 2023 Expired
US6987094 Optimized formulation of tobramycin for aerosolization 22 Sep, 2022 Expired
US7939502 Optimised formulation of tobramycin for aerosolization 14 Jun, 2022 Expired
US7049328 Use for deferiprone 28 Jun, 2021 Expired
US5856346 Short-acting dihydropyridines 05 Jan, 2021 Expired
US5712279 Inhibitors of microsomal triglyceride transfer protein and method 21 Feb, 2020 Expired
US6492365 Microsomal triglyceride transfer protein 10 Dec, 2019 Expired
US6114313 Pharmaceutical compositions for freeze drying 11 Dec, 2018 Expired
US5739152 Pharmaceutical emulsion 14 Apr, 2015 Expired
US5739135 Inhibitors of microsomal triglyceride transfer protein and method 14 Apr, 2015 Expired
US6183778 Pharmaceutical tablet capable of liberating one or more drugs at different release rates 21 Sep, 2013 Expired


Given below is the list of recent legal activities going on the following drug patents of Chiesi.

Activity Date Patent Number
Patent litigations
Electronic Review
Critical
07 Jun, 2024 US11969471
Payment of Maintenance Fee, 12th Year, Large Entity 03 Jun, 2024 US8329198
Email Notification
Critical
06 May, 2024 US11969471
Mail O.P. Petition Decision 06 May, 2024 US11969471
Mail-Record Petition Decision of Granted to Make Entity Status large 02 May, 2024 US11969471
Record Petition Decision of Granted to Make Entity Status large 01 May, 2024 US11969471
Recordation of Patent eGrant 30 Apr, 2024 US11969471
O.P. Petition Decision 30 Apr, 2024 US11969471
Recordation of Patent Grant Mailed
Critical
30 Apr, 2024 US11969471
Mail Patent eGrant Notification 30 Apr, 2024 US11969471
Email Notification
Critical
30 Apr, 2024 US11969471
Patent Issue Date Used in PTA Calculation
Critical
30 Apr, 2024 US11969471
Patent eGrant Notification 30 Apr, 2024 US11969471
Email Notification
Critical
11 Apr, 2024 US11969471
Issue Notification Mailed
Critical
10 Apr, 2024 US11969471


Chiesi's Drug Patent Litigations

Chiesi's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 01, 2014, against patent number US8455524. The petitioner Sandoz Inc., challenged the validity of this patent, with EKR Therapeutics, LLC as the respondent. Click below to track the latest information on how companies are challenging Chiesi's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7049328 May, 2017 Terminated-Settled
(07 Aug, 2018)
ApoPharma Inc. Taro
US7932268 August, 2015 FWD Entered
(06 Mar, 2017)
The Trustees of the University of Pennsylvania) Coalition for Affordable Drugs VIII
US8618135 August, 2015 Final Written Decision
(06 Mar, 2017)
The Trustees of the University of Pennsylvania COALITION FOR AFFORDABLE DRUGS VIII, LLC
US7612102 October, 2014 Terminated-Denied
(24 Apr, 2015)
EKR Therapeutics, LLC Sandoz Inc.
US7659291 October, 2014 Terminated-Denied
(24 Apr, 2015)
EKR Therapeutics, LLC Sandoz Inc.
US8455524 October, 2014 Terminated-Denied
(24 Apr, 2015)
EKR Therapeutics, LLC Sandoz Inc.


Chiesi Drug Patents' Oppositions Filed in EPO

Chiesi drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 21, 2013, by Stein, Evan Md Phd. This opposition was filed on patent number EP05724887A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP11833207A Dec, 2015 Fresenius Kabi Deutschland GmbH Patent maintained as amended
EP05724887A Aug, 2013 Stein, Evan MD PhD Patent maintained as amended


Chiesi's Family Patents

Chiesi drugs have patent protection in a total of 47 countries. It's US patent count contributes only to 32.8% of its total global patent coverage. 11 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Chiesi Drug List

Given below is the complete list of Chiesi's drugs and the patents protecting them.


1. Bethkis

Bethkis is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7696178 Optimised formulation of tobramycin for aerosolization 17 Mar, 2023
(1 year, 9 months ago)
Expired
US6987094 Optimized formulation of tobramycin for aerosolization 22 Sep, 2022
(2 years ago)
Expired
US7939502 Optimised formulation of tobramycin for aerosolization 14 Jun, 2022
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bethkis's drug page


2. Cardene In 0.83% Sodium Chloride In Plastic Container

Cardene In 0.83% Sodium Chloride In Plastic Container is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7612102 Pre-mixed, ready-to-use pharmaceutical compositions 26 Dec, 2027
(3 years from now)
Active
US9364564 Pre-mixed, ready-to-use pharmaceutical compositions 26 Dec, 2027
(3 years from now)
Active
US10758616 Pre-mixed, ready-to-use pharmaceutical compositions 18 Apr, 2027
(2 years from now)
Active
US11547758 Pre-mixed, ready-to-use pharmaceutical compositions 18 Apr, 2027
(2 years from now)
Active
US7659291 Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions 18 Apr, 2027
(2 years from now)
Active
US8455524 Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions 18 Apr, 2027
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cardene In 0.83% Sodium Chloride In Plastic Container's drug page


3. Cardene In 0.86% Sodium Chloride In Plastic Container

Cardene In 0.86% Sodium Chloride In Plastic Container is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7612102 Pre-mixed, ready-to-use pharmaceutical compositions 26 Dec, 2027
(3 years from now)
Active
US9364564 Pre-mixed, ready-to-use pharmaceutical compositions 26 Dec, 2027
(3 years from now)
Active
US10758616 Pre-mixed, ready-to-use pharmaceutical compositions 18 Apr, 2027
(2 years from now)
Active
US11547758 Pre-mixed, ready-to-use pharmaceutical compositions 18 Apr, 2027
(2 years from now)
Active
US7659291 Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions 18 Apr, 2027
(2 years from now)
Active
US8455524 Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions 18 Apr, 2027
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cardene In 0.86% Sodium Chloride In Plastic Container's drug page


4. Cardene In 4.8% Dextrose In Plastic Container

Cardene In 4.8% Dextrose In Plastic Container is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7612102 Pre-mixed, ready-to-use pharmaceutical compositions 26 Dec, 2027
(3 years from now)
Active
US9364564 Pre-mixed, ready-to-use pharmaceutical compositions 26 Dec, 2027
(3 years from now)
Active
US10758616 Pre-mixed, ready-to-use pharmaceutical compositions 18 Apr, 2027
(2 years from now)
Active
US11547758 Pre-mixed, ready-to-use pharmaceutical compositions 18 Apr, 2027
(2 years from now)
Active
US7659291 Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions 18 Apr, 2027
(2 years from now)
Active
US8455524 Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions 18 Apr, 2027
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cardene In 4.8% Dextrose In Plastic Container's drug page


5. Cardene In 5.0% Dextrose In Plastic Container

Cardene In 5.0% Dextrose In Plastic Container is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7612102 Pre-mixed, ready-to-use pharmaceutical compositions 26 Dec, 2027
(3 years from now)
Active
US9364564 Pre-mixed, ready-to-use pharmaceutical compositions 26 Dec, 2027
(3 years from now)
Active
US7659291 Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions 18 Apr, 2027
(2 years from now)
Active
US8455524 Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions 18 Apr, 2027
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cardene In 5.0% Dextrose In Plastic Container's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Cleviprex

Cleviprex is protected by 5 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10010537 Clevidipine emulsion formulations containing antimicrobial agents 10 Oct, 2031
(6 years from now)
Active
US11103490 Clevidipine emulsion formulations containing antimicrobial agents 10 Oct, 2031
(6 years from now)
Active
US8658676 Clevidipine emulsion formulations containing antimicrobial agents 10 Oct, 2031
(6 years from now)
Active
US5856346 Short-acting dihydropyridines 05 Jan, 2021
(3 years ago)
Expired
US5739152 Pharmaceutical emulsion 14 Apr, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cleviprex's drug page


7. Ferriprox

Ferriprox is protected by 8 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10780055 Delayed release deferiprone tablets and methods of using the same 25 Oct, 2038
(13 years from now)
Active
US10940115 Delayed release deferiprone tablets and methods of using the same 25 Oct, 2038
(13 years from now)
Active
US10940116 Delayed release deferiprone tablets and methods of using the same 25 Oct, 2038
(13 years from now)
Active
US11357731 Delayed release deferiprone tablets and methods of using the same 25 Oct, 2038
(13 years from now)
Active
US11458103 Delayed release deferiprone tablets and methods of using the same 25 Oct, 2038
(13 years from now)
Active
US11723874 Delayed release deferiprone tablets and methods of using the same 25 Oct, 2038
(13 years from now)
Active
US8703156 Liquid formulation for deferiprone with palatable taste 26 Oct, 2029
(4 years from now)
Active
US7049328 Use for deferiprone 28 Jun, 2021
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ferriprox's drug page


8. Filsuvez

Filsuvez is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11083733 Betulin-containing birch bark extracts and their formulation 04 Jan, 2039
(14 years from now)
Active
US11266660 Betulin-containing birch bark extracts and their formulation 04 Jan, 2039
(14 years from now)
Active
US9352041 Use of an oleogel containing triterpene for healing wounds 24 Nov, 2030
(5 years from now)
Active
US9827214 Use of an oleogel containing triterpene for healing wounds 24 Nov, 2030
(5 years from now)
Active
US8828444 Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel 21 Jun, 2025
(5 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Filsuvez's drug page


9. Juxtapid

Juxtapid is protected by 12 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7932268 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects 19 Aug, 2027
(2 years from now)
Active
US10016404 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects 07 Mar, 2025
(2 months from now)
Active
US10555938 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects 07 Mar, 2025
(2 months from now)
Active
US8618135 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects 07 Mar, 2025
(2 months from now)
Active
US9265758 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects 07 Mar, 2025
(2 months from now)
Active
US9364470 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects 07 Mar, 2025
(2 months from now)
Active
US9433617 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects 07 Mar, 2025
(2 months from now)
Active
US9861622 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects 07 Mar, 2025
(2 months from now)
Active
US5712279 Inhibitors of microsomal triglyceride transfer protein and method 21 Feb, 2020
(4 years ago)
Expired
US6492365 Microsomal triglyceride transfer protein 10 Dec, 2019
(5 years ago)
Expired
US5739135 Inhibitors of microsomal triglyceride transfer protein and method 14 Apr, 2015
(9 years ago)
Expired
US5712279 Inhibitors of microsomal triglyceride transfer protein and method 21 Feb, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Juxtapid's drug page


10. Kengreal

Kengreal is protected by 10 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10039780 Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same 10 Jul, 2035
(10 years from now)
Active
US9295687 Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same 10 Jul, 2035
(10 years from now)
Active
US9439921 Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same 10 Jul, 2035
(10 years from now)
Active
US9700575 Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same 10 Jul, 2035
(10 years from now)
Active
US8680052 Methods of treating, reducing the incidence of, and/or preventing ischemic events 09 Mar, 2033
(8 years from now)
Active
US9427448 Methods of treating, reducing the incidence of, and/or preventing ischemic events 10 Nov, 2030
(5 years from now)
Active
US8759316 Maintenance of platelet inhibition during antiplatelet therapy 13 May, 2029
(4 years from now)
Active
US9925265 Methods of treating or preventing stent thrombosis 13 May, 2029
(4 years from now)
Active
US6130208 Formulation containing a nucleotide analogue 29 Jun, 2023
(1 year, 5 months ago)
Expired
US6114313 Pharmaceutical compositions for freeze drying 11 Dec, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kengreal's drug page


11. Mycapssa

Mycapssa is protected by 14 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11141457 Oral octreotide therapy and contraceptive methods 28 Dec, 2040
(16 years from now)
Active
US11890316 Oral octreotide therapy and contraceptive methods 28 Dec, 2040
(16 years from now)
Active
US10238709 Method of treating diseases 03 Feb, 2036
(11 years from now)
Active
US10695397 Method of treating diseases 03 Feb, 2036
(11 years from now)
Active
US11052126 Method of treating diseases 03 Feb, 2036
(11 years from now)
Active
US11338011 Method of treating diseases 03 Feb, 2036
(11 years from now)
Active
US11510963 Method of treating diseases 03 Feb, 2036
(11 years from now)
Active
US11857595 Method of treating diseases 03 Feb, 2036
(11 years from now)
Active
US11969471 Pharmaceutical compositions and related methods of delivery 17 Sep, 2029
(4 years from now)
Active
US11986529 Pharmaceutical compositions and related methods of delivery 17 Sep, 2029
(4 years from now)
Active
US8329198 Pharmaceutical compositions and related methods of delivery 17 Sep, 2029
(4 years from now)
Active
US8535695 Pharmaceutical compositions and related methods of delivery 17 Sep, 2029
(4 years from now)
Active
US9265812 Pharmaceutical compositions and related methods of delivery 17 Sep, 2029
(4 years from now)
Active
US9566246 Pharmaceutical compositions and related methods of delivery 17 Sep, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mycapssa's drug page


12. Zyflo Cr

Zyflo Cr is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6183778 Pharmaceutical tablet capable of liberating one or more drugs at different release rates 21 Sep, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zyflo Cr's drug page